Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2006

View Archived Issues

Janssen claims new anxiolytics in patent literature

Anthrax vaccine rPA-102 well tolerated, induces antibody responses in humans

Bicifadine well tolerated, improves low back pain in clinical studies

Trial data reveal efficacy and safety of extended-release paliperidone ER in schizophrenia

Recent patents impart new therapeutic agents for cancer

AEE-788 effective in an animal model of thyroid cancer

Phase II data on combretastatin A-4 phosphate in ATC warrants future trials

MerLion completes merger with Combinature Biopharm and Athelas

Medarex and GenPat77 to develop antibody products for autoimmune diseases

Auriga and Degussa to develop corticosteroid formulation for GI diseases

NIH to study prime-boost approach in HIV

Citalopram prevents depression in patients undergoing treatment for head and neck cancer

Once-daily dosing of oral methylnaltrexone studied in phase II trial

GammaCan and Life Therapeutics sign term sheet for VitiGam collaboration

Diamyd shows efficacy in phase II type 1 diabetes study

Innovive licenses patent rights to novel doxorubicin prodrug

Further positive phase II findings for Trinam

Phase III results for telavancin in cSSSI

Fresenius Kabi and Sandoz to develop HESylated biopharmaceutical

Acthar Gel sNDA in infantile spasms accepted for review

CE Mark for Repel-CV to reduce adhesions following cardiac surgery

Keppra receives FDA approval for juvenile myoclonic epilepsy

Garenoxacin submission withdrawn in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...